GSK’s New Study on Multiple Myeloma Treatment: What Investors Need to Know

GlaxoSmithKline ((GSK)), GlaxoSmithKline plc (UK) ((GB:GSK)) announced an update on their ongoing clinical study.

GlaxoSmithKline (GSK) is conducting a Phase 3 clinical study titled A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM). The study aims to evaluate whether the BRd combination can prolong progression-free survival and improve minimal residual disease negative status compared to the DRd regimen in patients with TI-NDMM.

The study tests two treatment regimens: the experimental arm with Belantamab Mafodotin, Lenalidomide, and Dexamethasone, and the active comparator arm with Daratumumab, Lenalidomide, and Dexamethasone. These drugs are intended to treat patients with newly diagnosed multiple myeloma who cannot undergo stem cell transplantation.

This interventional study is randomized with a parallel assignment model and no masking, focusing on treatment as the primary purpose. Participants are allocated to one of the two treatment arms to compare the effectiveness of the drug combinations.

The study began on December 27, 2024, with the last update submitted on August 5, 2025. These dates are crucial as they mark the study’s progress and the timeline for potential results that could impact the market.

For investors, this study could influence GSK’s stock performance, especially if the results show a significant improvement in treatment outcomes. The competitive landscape in the multiple myeloma treatment market includes other major pharmaceutical companies, which could also affect investor sentiment.

The study is currently recruiting, and further details are available on the ClinicalTrials portal.